View printer-friendly version << Back
Pediatrix Expects Name Change to MEDNAX, Inc., to Be Completed by Year-End

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Dec. 29, 2008--Pediatrix Medical Group, Inc. (NYSE: PDX), expects that its previously announced name change to MEDNAX, Inc., will be completed by December 31, 2008. Each share of Pediatrix will become a share of MEDNAX, and will trade on the New York Stock Exchange under the ticker symbol "MD," when the U.S. securities markets open January 2, 2009.

MEDNAX is being organized as a holding company whose principal subsidiaries will be Pediatrix Medical Group and American Anesthesiology. Pediatrix encompasses the Company's historic physician services in the neonatal, maternal-fetal, pediatric cardiology and pediatric intensive care subspecialties, as well as the Company's newborn hearing screen program. American Anesthesiology, which was formed in 2007, includes anesthesia practices in northern Virginia, Atlanta, Georgia, and Raleigh, North Carolina.

About Pediatrix

Pediatrix Medical Group, Inc. is the nation's leading provider of neonatal, maternal-fetal and pediatric physician subspecialty services and recently expanded to include anesthesiology services. Pediatrix physicians and advanced practitioners are reshaping the delivery of care within the maternal-fetal, neonatal intensive care and pediatric cardiology subspecialties, using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide high-quality, cost-effective care. Founded in 1979, its neonatal physicians provide services at more than 250 neonatal intensive care units, and in many markets they collaborate with affiliated maternal-fetal medicine, pediatric cardiology physician subspecialists and pediatric intensivists to provide a clinical care continuum. Combined, Pediatrix and its affiliated professional corporations employ more than 1,200 physicians in 32 states and Puerto Rico. Pediatrix is also the nation's largest provider of newborn hearing screens. Additional information is available at

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made by Pediatrix's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in Pediatrix's most recent Annual Report on Form 10-K, including the section entitled "Risk Factors."

CONTACT: Pediatrix Medical Group, Inc.
Bob Kneeley, 954-384-0175, x-5300
Director, Investor Relations

Source: Pediatrix Medical Group, Inc.